Abstract
Abstract It is maintained that much research into the design and analysis of cross-over trials has been of little practical relevance to drug development. The point is illustrated using three topics: the AB/BA design, bioequivalence and multi-period designs in two treatments. It is suggested that statisticians should pay more attention to the work of fellow scientists, in particular, in the field of pharmacokinetics, and also that the philosophical–inferential base employed in examining cross-over trials has often been too narrow.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
